万赛维适应症

The main component of (Valcyte) is valganciclovir hydrochloride. Valganciclovir is the L-valyl ester (prodrug) of ganciclovir. After oral administration, it is rapidly converted into ganciclovir by esterases in the small intestine and liver. Ganciclovir is a synthetic 2'-deoxyguanosine analog that inhibits herpes virus replication in vitro and in vivo. Susceptible human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV), and hepatitis B virus.

In cells infected with cytomegalovirus (CMV), ganciclovir is first phosphorylated by the viral protein kinase UL97 to ganciclovir monophosphate. It is further phosphorylated by intracellular protein kinases into ganciclovir triphosphate, which is then slowly metabolized within the cell. After removal of extracellular ganciclovir, the observed half-life of ganciclovir in HSV- or HCMV-infected cells was 18 hours (6-24 hours), respectively. Since the phosphorylation process relies heavily on viral protein kinases, ganciclovir phosphorylation occurs preferentially in virus-infected cells.

What are the main indications of Vansavi?

In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients. On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Valcyte for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. Prevention of CMV Infection in Transplant Patients: For patients who have received a solid organ transplant, the recommended dose of Valcyte is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.